Investigating how variations in a protein affect Alzheimer's disease and Down syndrome.
Effect of APP copy number variants in Alzheimer's disease and and Down Syndrome on Reelin expression and function
['FUNDING_SBIR_1'] · REELIN THERAPEUTICS, INC. · NIH-10895540
This study is looking at how a protein called Reelin affects brain health in people with Alzheimer's and Down syndrome, and it will test whether certain antibodies can help reduce inflammation and improve brain function in a mouse model of Down syndrome, with the hope of finding new treatments for patients.
Quick facts
| Phase | ['FUNDING_SBIR_1'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | REELIN THERAPEUTICS, INC. (nih funded) |
| Locations | 1 site (SAN DIEGO, UNITED STATES) |
| Trial ID | NIH-10895540 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of a protein called Reelin in the context of Alzheimer's disease and Down syndrome. It aims to explore how changes in the number of copies of the APP gene influence Reelin expression and function, which is linked to inflammation and brain damage. The researchers will use a mouse model of Down syndrome to test the effects of anti-Reelin antibodies, which may help reduce inflammation and improve brain health. By identifying effective antibodies, the study seeks to pave the way for new therapeutic options for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with Alzheimer's disease or Down syndrome.
Not a fit: Patients with other forms of dementia or neurological disorders unrelated to Alzheimer's disease or Down syndrome may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that reduce inflammation and improve outcomes for patients with Alzheimer's disease and Down syndrome.
How similar studies have performed: Previous research has shown promise in targeting inflammatory pathways in Alzheimer's disease, suggesting that this approach may yield beneficial results.
Where this research is happening
SAN DIEGO, UNITED STATES
- REELIN THERAPEUTICS, INC. — SAN DIEGO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KOUNNAS, MARIA Z — REELIN THERAPEUTICS, INC.
- Study coordinator: KOUNNAS, MARIA Z
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia, Alzheimer syndrome, Alzheimer's Disease, Alzheimer's disease biological marker, Alzheimer's disease patient